Pathophysiology of childhood polycystic kidney diseases: new insights into disease-specific therapy.
Pediatr Res
; 75(1-2): 148-57, 2014 Jan.
Article
en En
| MEDLINE
| ID: mdl-24336431
ABSTRACT
Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are significant causes of morbidity and mortality in children and young adults. ADPKD, with an incidence of 1400 to 11,000, affects more than 13 million individuals worldwide and is a major cause of end-stage renal disease in adults. However, symptomatic disease is increasingly recognized in children. ARPKD is a dual-organ hepatorenal disease with an incidence of 120,000 to 140,000 and a heterozygote carrier rate of 1 in 70. Currently, no clinically significant disease-specific therapy exists for ADPKD or ARPKD. The genetic basis of both ADPKD and ARPKD have been identified, and delineation of the basic molecular and cellular pathophysiology has led to the discovery that abnormal ADPKD and ARPKD gene products interact to create "polycystin complexes" located at multiple sites within affected cells. The extracellular matrix and vessels produce a variety of soluble factors that affect the biology of adjacent cells in many dynamic ways. This review will focus on the molecular and cellular bases of the abnormal cystic phenotype and discuss the clinical translation of such basic data into new therapies that promise to alter the natural history of disease for children with genetic PKDs.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Riñón Poliquístico Autosómico Recesivo
/
Riñón Poliquístico Autosómico Dominante
/
Riñón
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Animals
/
Child
/
Child, preschool
/
Humans
/
Infant
Idioma:
En
Revista:
Pediatr Res
Año:
2014
Tipo del documento:
Article